Novel inhibitors of NRH:Quinone oxidoreductase 2 (NQO2): Crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones

Mark S. Dunstan, John Barnes, Matthew Humphries, Roger C. Whitehead, Richard A. Bryce, David Leys, Ian J. Stratford, Karen A. Nolan

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Imidazoacridin-6-ones are shown to be potent nanomolar inhibitors of the enzyme NQO2. By use of computational molecular modeling, a reliable QSAR was established, relating inhibitory potency with calculated binding affinity. Further, crystal structures of NQO2 containing two of the imidazoacridin-6-ones have been solved. To generate compounds with reduced off-target (DNA binding) effects, an N-oxide moiety was introduced into the tertiary aminoalkyl side chain of the imidazoacridin-6-ones. This resulted in substantially less toxicity in a panel of eight cancer cell lines, decreased protein binding, and reduced DNA binding and nuclear accumulation. Finally, one of the N-oxides showed potent ability to inhibit the enzymatic function of NQO2 in cells, and therefore, it may be useful as a pharmacological probe to study the properties of the enzyme in vitro and in vivo. © 2011 American Chemical Society.
    Original languageEnglish
    Pages (from-to)6597-6611
    Number of pages14
    JournalJournal of Medicinal Chemistry
    Volume54
    Issue number19
    DOIs
    Publication statusPublished - 13 Oct 2011

    Fingerprint

    Dive into the research topics of 'Novel inhibitors of NRH:Quinone oxidoreductase 2 (NQO2): Crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones'. Together they form a unique fingerprint.

    Cite this